Evidence map›Paper›PMID 42110904›Full record

ArticleAlpha psychiatry2026

Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study.

Wei Li, Jinghui Tong, Xiaoxiao Gao, Hu Deng, Zezhi Li, Junhong Zhu, Jiahong Liu, Yanchi Zhang, Dengtang Liu, Xiaobin Zhang and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alpha psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Wei LiPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.ORCID https://orcid.org/0009-0001-1647-8485
Jinghui TongPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.ORCID https://orcid.org/0000-0002-8551-315X
Xiaoxiao GaoPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
Hu DengPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
Zezhi LiThe Affiliated Brain Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and The Ministry of Education of China, Guangzhou Medical University, 510370 Guangzhou, Guangdong, China.ORCID https://orcid.org/0000-0001-9149-5800
Junhong ZhuThe Affiliated Wuhan Mental Health Center of Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei, China.ORCID https://orcid.org/0009-0000-2307-2363
Jiahong LiuZhejiang Provincial Clinical Research Center for Mental Health, The Affiliated Kangning Hospital of Wenzhou Medical University, 325007 Wenzhou, Zhejiang, China.ORCID https://orcid.org/0009-0009-4131-6101
Yanchi ZhangDepartment of Psychology, The Sixth Hospital of Changchun, 130052 Changchun, Jilin, China.ORCID https://orcid.org/0009-0006-8730-1368
Dengtang LiuShanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, 200030 Shanghai, China.ORCID https://orcid.org/0000-0002-0813-6848
Xiaobin ZhangThe Affiliated Guangji Hospital of Soochow University, 215137 Suzhou, Jiangsu, China.
Jianping TangAffiliated Mental Health Center & Hangzhou Seventh People' s Hospital, Zhejiang University School of Medicine, 310013 Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0000-2126-7394
Yuxiu SuiDepartment of Psychiatry, Nanjing Brain Hospital, 210029 Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0002-9364-4686
Hezeng YangDepartment of Psychiatry, Shenzhen Kangning Hospital, 518118 Shenzhen, Guangdong, China.ORCID https://orcid.org/0000-0003-2664-7155
Yunshu ZhangHebei Key Laboratory of Major Mental and Behavioral Disorders, The Sixth People's Hospital of Hebei Province, 071000 Baoding, Hebei, China.ORCID https://orcid.org/0009-0009-9307-4335
Chao LiDepartment of Clinical psychology, Xi'an Mental Health Center, 710061 Xi'an, Shaanxi, China.ORCID https://orcid.org/0009-0007-0453-3460
Xuhui ZhouDepartment of Addiction Medicine, Brain Hospital of Hunan Province (The Second People's Hospital of Hunan Province), 410007 Changsha, Hunan, China.
Baoping XingZhejiang Mental Health Center, Tongde Hospital of Zhejiang Province, 310012 Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0001-8446-9521
Yi WangTianjin Anding Hospital, Mental Health Center of Tianjin Medical University, 300222 Tianjin, China.ORCID https://orcid.org/0009-0007-4196-6097
Jiaqi SongPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
Rongzhen ZhangPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
Yang ShenPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
Yanying SongPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
Yanfang ZhouPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
Shujuan PanPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
Wei ZhengThe Affiliated Brain Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and The Ministry of Education of China, Guangzhou Medical University, 510370 Guangzhou, Guangdong, China.
Yunlong TanPeking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.ORCID https://orcid.org/0000-0002-3522-3912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-acting injectable (LAI) antipsychotics improve adherence and promote long-term recovery in schizophrenia spectrum disorders (SSD). Risperidone Microspheres for Injection (II) (RMI-II), a novel LAI formulation, offers rapid symptom control with a 2-week dosing interval. However, real-world evidence regarding its efficacy and safety remains limited. Methods: A prospective, single-arm, multicenter study was conducted across 15 Chinese research centers. Eligible patients (n = 228) met DSM-5 criteria for SSD, had a Positive and Negative Syndrome Scale (PANSS) total score ≥70, and were followed for 12 weeks. Patients received RMI-II (25-50 mg/2 weeks) via intramuscular injection. Results: Among 228 patients (50.88% male, mean age [37.00 ± 12.82] years) receiving RMI-II, the PANSS total score decreased significantly by 14.02 (3.22, 24.85) at week 2 ( Conclusions: RMI-II appeared to be effective and well-tolerated in reducing acute psychotic symptoms. These findings suggest it may represent an additional therapeutic option for SSD. Clinical Trial Registration: No: ChiCTR2200066865, 20 December 2022, https://www.chictr.org.cn/showproj.html?proj=183302.

Indexed as

long-acting injectable antipsychoticspositive and negative syndrome scalereal-world studyrisperidone microspheresschizophrenia spectrum disorders

Identifiers

PMID42110904
PMCPMC13156047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.